Overall Survival (OS) as a Function of the Number of Therapeutic Lines in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDpNET) Abstract #831

Introduction: At least 9 therapeutic options are now available for unresectable WDpNET patients. Whether all lines can be administrated before tumor or toxic-related deaths is currently unknown.
Aim(s): The primary endpoint was to determine OS as a function of the number of therapeutic lines. Secondary endpoints were to determine cumulative toxicity as defined by the frequency of modified serious adverse events (mSAE) as a function of the number of lines.
Materials and methods: Patients with unresectable WDpNET treated between 1998 and 2010 at the Gustave Roussy were studied. Locoregional (TACE) and systemic lines including somatostatin analogs or interferon[48 patients], targeted therapies (sunitinib, everolimus)[46], PRRT[26], chemotherapies (dacarbazine-, streptozotocin-, oxaliplatin-based)[82] were counted. Cumulative toxicity was defined by mSAE, including permanent toxicity (persistent grade 2-5).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Amandine Berdelou
Keywords: pNets

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?
Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Medical Doctor Vincenzo Marotta
Authors: Marotta V, Malka D, Walter T, Do Cao C, ...
#1244 Everolimus in Progressive Metastatic Pancreatic Neuroendocrine Tumors: Analyses of Median Progression Free Survival and Safety in the Real Life Setting
Introduction: Everolimus is an oral inhibitor of mammalian target of rapamycin(mTOR) with antitumor activity in patients(pts) with pancreatic neuroendocrine tumor(pNET)s
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Michela Del Prete
#1845 Mismatch Repair (MMR) Protein Expression is Uncommon in Poorly Differentiated Neuroendocrine Carcinoma
Introduction: Microsatellite instability (MSI) has been reported to occur in a significant proportion of neuroendocrine carcinoma (NEC) and mixed adenoneuroendocrine carcinomas (MANEC) (11 out of 89 cases, Sahnane et al, ERC 2015). It might be predictive of response to immunotherapy.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: Dr Julien Hadoux
#1537 Antitumor Efficacy of Temozolomide in Patients with Metastatic Pulmonary Carcinoids
Introduction: Temodal (TMZ) is an oral alternative to dacarbazine.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Diana Bello Roufai
#1922 Comparison of Long Terms Outcomes after Resection of Hepatic and /or Peritoneal Metastasis from Neuroendocrine Tumors
Introduction: The complete resection of liver metastasis LM is usually recommended in patients with grade 1-2 NET. The exact benefit of resection of peritoneal metastasis PM is unknown.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: LĂ©onor Benhaim
Authors: Benhaim L, Faron M, Gelli M, Boige V, ...